Bloomberg BusinessweekBloomberg Businessweek

Ozempic’s Success Is Bad News for Rivals

View descriptionShare

Bloomberg News Health Reporter Madison Muller discusses how the drug Ozempic could cut demand for big-money drugs targeting a wide range of maladies, even Alzheimer’s.
Hosts: Carol Massar and Tim Stenovec. Producer: Paul Brennan.

 
  • Facebook
  • X (Twitter)
  • WhatsApp
  • Email
  • Download

In 1 playlist(s)

Bloomberg Businessweek

Listen for reporting from the magazine that helps global leaders stay ahead. Hosts Carol Massar an 
Social links
Follow podcast
Recent clips
Browse 5,147 clip(s)